Spots Global Cancer Trial Database for Microwave Plus Chemotherapy Versus Chemotherapy for Advanced NSCLC

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Microwave Plus Chemotherapy Versus Chemotherapy for Advanced NSCLC

Official Title: A Multicenter, Randomized, Open-label Phase III Trial of Microwave Plus Chemotherapy Versus Chemotherapy for Advanced NSCLC

Study ID: NCT02455843

Conditions

Non Small Cell Lung Cancer

Interventions

Microwave ablation

Study Description

Brief Summary: This study is a multicenter, randomized, open-label Phase III trial that compares microwave plus chemotherapy versus chemotherapy in patients with advanced non-small cell lung cancer. The primary endpoint is progression free survival (PFS) and the key secondary endpoint is overall survival (OS). A total of 275 eligible patients will be randomized to receive either microwave ablation combinated with first-line platinum-based doublet chemotherapy（138） or first-line platinum-based doublet chemotherapy（137） in a 1:1 ratio until patients. The response of microwave ablation will be assessed by the expert consensus for thermal ablation of primary and metastatic lung tumors. Tumor response and progression will be assessed according to Response Evaluation Criteria in Solid Tumors（RECIST）1.1.

Detailed Description: Patients will be randomized to treated with microwave ablation and chemotherapy or treated with chemotherapy alone.